Additionally, the combined 7.16.4 mAb treatment and Cpt1a deletion reduced the size and number of lung metastatic lesions, indicating the potential efficacy of this combination therapy in both primary and metastatic disease (Supplementary Fig. 12b). This evidence concerns the gene CPT1A and metastatic neoplasm.